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Abstract
Due to their high prevalence, retinal vascular diseases including age related macular degeneration (AMD), retinal vein
occlusions (RVO), diabetic retinopathy (DR) and diabetic macular edema have been major therapeutic targets over the last
years. The pathogenesis of these diseases is complex and yet not fully understood. However, increased proliferation,
migration and angiogenesis are characteristic cellular features in almost every retinal vascular disease. The introduction of
vascular endothelial growth factor (VEGF) binding intravitreal treatment strategies has led to great advances in the therapy
of these diseases. While the predominant part of affected patients benefits from the specific binding of VEGF by
administering an anti-VEGF antibody into the vitreous cavity, a small number of non-responders exist and alternative or
additional therapeutic strategies should therefore be evaluated. The mammalian target of rapamycin (mTOR) is a central
signaling pathway that eventually triggers up-regulation of cellular proliferation, migration and survival and has been
identified to play a key role in angiogenesis. In the present study we were able to show that both retinal pigment epithelial
(RPE) cells as wells as human umbilical vein endothelial cells (HUVEC) are inhibited in proliferating and migrating after
treatment with temsirolimus in non-toxic concentrations. Previous studies suggest that the production of VEGF, platelet
derived growth factor (PDGF) and other important cytokines is not only triggered by hypoxia but also by mTOR itself. Our
results indicate that temsirolimus decreases VEGF and PDGF expression on RNA and protein levels significantly. We
therefore believe that the mTOR inhibitor temsirolimus might be a promising drug in the future and it seems worthwhile to
evaluate complementary therapeutic effects with anti-VEGF drugs for patients not profiting from mono anti-VEGF therapy
alone.
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Introduction
Age related macular degeneration (AMD), macular edema (ME)
following retinal vein occlusions (RVO) and diabetic macular
edema (DME) as a complication of diabetic retinopathy (DR) are
major reasons for severe vision loss and legal blindness in the
western world [1–3]. With an expected increase in patients
suffering from diabetes mellitus as well as the rising mean age of
the population over the next decades even more patients will be
affected in the future resulting in a tremendous socio-economic
burden [4].
The pathogenesis of retinal vascular disease is complex and yet
not fully understood [5,6]. However, cellular proliferation and
vascular leakage are found in AMD, ME following RVO, as well
as in DME, resulting in pathologic fluid accumulation in the
macular area. Moreover is (sub)retinal neovascularization in AMD
a severe complication and evidence exists, that this event is mainly
triggered by proliferation and migration of endothelial and retinal
pigment epithelial cells [7]. In addition, it is well known that
besides a mechanical defect in different structures, such as the
endothelium in retinal vessels and the outer blood retinal barrier
formed by the retinal pigment epithelium and Bruchs membrane,
a common underlying mechanism includes the increased produc-
tion of angiogenic and inflammatory components due to increased
hypoxic retinal conditions [8–11]. Although it is sufficiently clear,
that the three diseases are different in their development and
pathological sequence, it has been shown, that hypoxia and the
deregulation of a large number of various growth factors such as
platelet derived growth factor (PDGF), placenta derived growth
factor (PlGF), connective tissue growth factor (CTGF) and
particularly vascular endothelial growth factor (VEGF) play a
crucial role in their etiopathologies [12–15]. Based on this
knowledge selective intravitreal inhibition of VEGF has become
a safe and effective primary treatment approach in the therapy of
neovascular AMD, ME following RVO, and DME, as well as in
several other ocular conditions that are characterized by macular
edema. Today, the intravitreal injection of VEGF antibodies such
as bevacizumab and ranibizumab or fusion proteins such as
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aflibercept [16,17] have therefore become common clinical
practice. Large studies (e.g. RESOLVE, MARINA or VIEW)
could clearly show that a significant number of patients suffering
from macular edema improved in terms of edema resolution as
well as visual acuity [18–20]. However, a number of patients do
not improve from this treatment and for these cases alternative
treatment options should be investigated.
Hypoxia plays a central role in the development and
progression of retinal vascular diseases. A number of studies could
clearly link hypoxia with several retinal diseases characterized by
retinal ischemia and subsequent pathological angiogenesis involv-
ing the up-regulation of VEGF and other VEGF-related
polypeptides such as PlGF [21–23]. The binding of these
VEGF-family proteins to their receptor tyrosine kinases
VEGFR-1, VEGFR-2 and VEGFR-3 is followed by numerous
downstream effects leading to proliferation, cell migration,
vascular permeability and endothelial inflammation. The most
angiogenic effect of VEGF in-vivo is linked with its binding to
VEGFR-2 [24]. One of the most important signaling pathways
among several downstream of VEGFR-2 is PI3K/Akt [25,26]
which subsequently activates the mammalian target of Rapamycin
(mTOR) [27]. mTOR is a serine-threonine protein kinase that
plays an important role in signal transduction pathways that
control cell growth and angiogenesis and has been a target to
many cancer therapy approaches in-vitro and in-vivo [28,29].
Temsirolimus is an ester derivative of sirolimus with enhanced
pharmaceutical properties including improved stability and
solubility and binds to a cytoplasmatic protein. This complex
binds and inhibits mTOR and proved its potency in several
clinical and laboratory studies [30–33].
We therefore evaluated the effect of temsirolimus on cellular
events associated with retinal vascular diseases such as neovascular
AMD and DR on retinal pigment epithelial cells and human
umbilical vein endothelial cells as a common model for endothelial
cells in vision research in an in-vitro model.
Methods
Ethics
The methods of securing human tissue were humane, complied
with the Declaration of Helsinki, and were approved by the local
ethics committee and institutional review board at Ludwig-
Maximilians-University in Munich, Germany (file number
AKIRB-20123). Samples were procured from our tissue bank
(’’Bayerische Gewebebank Bavarian Tissue Banking GmbH‘‘,
http://www.klinikum.uni-muenchen.de/Augenklinik-und-
Poliklinik/de/forschung-lehre/arbeitsgruppen/hornhautbank/
index.html) and written informed consent was obtained before









LC Laboratories, Woburn, MA, USA) was dissolved in 100%
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA) and
diluted with DMSO and the appropriate cell culture medium to
the desired concentration with a final DMSO concentration of
0.1% for in vitro studies. DMSO was added to cultures at 0.1%
(v/v) as a solvent control.
Human RPE Cell Culture
Primary RPE cells from four human donors (aged 34, 47, 51,
and 59 years old, obtained 3-10 h postmortem) without any history
of eye disease were obtained from the Eye Bank of Ludwig
Maximilian University and were prepared as previously de-
scribed.[34] Dulbecco modified Eagle medium (DMEM; Bio-
chrom, Berlin, Germany) supplemented with 10% fetal calf serum
(FCS; Biochrom) was used as the cell culture medium. Primary
human RPE cells of passage 3 to 7 were used for experiments.
HUVEC Culture
Cultures of human umbilical vein endothelial cells (HUVEC)
were purchased from Promocell (Heidelberg, Germany) and
cultured according to the manufacturer’s instructions. Endothelial
cell growth medium (ECGM; Promocell) with 5% FCS (Biochrom)
was used as the cell culture medium. The experiments were
conducted on HUVECs of passages 3 to 5.
Treatment of Cell Cultures
For methylthiotetrazole (MTT; 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide) assays, cells were seeded in 6-
well plates. For all other cell culture experiments, HUVECs or
RPE cells were seeded in 35-mm tissue culture dishes and cultured
on confluence in darkness. None of the used cell culture substrates
were coated with anything aside of the polycarbonate membrane,
that was coated with fibronectin and used in the boyden chamber
assay.
For all experiments except proliferation and migration, before
treatment, HUVECs or RPE cells were kept for 24 h in serum-free
conditions. Then, for MTT testing regarding viability and
proliferation, temsirolimus was added to reach final concentrations
of 0.005, 0.05, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/
mL.
As a result from viability testing and additional molecular pre-
testing, temsirolimus at a final concentration of 0.05 mg/mL was
chosen for all further experiments regarding growth factor
expression.
Hypoxic Stimulation
For hypoxia experiments, primary human RPE cells and
HUVECs were grown to confluence. Human RPE cells were
then washed and incubated overnight in serum-free medium. For
hypoxic stimulation, dishes were placed in an incubator with 1%
O2, 5% CO2, and 94% N2 in humidified atmosphere, for 24h.
The controls were kept in humidified atmosphere of 5% CO2 in
air at 37uC for the same time period.
MTT Assay
The MTT assay was used to determine the cell survival rate.
The MTT assay, which is well established for the assessment of cell
viability, was performed as described by Mosmann, with some
modifications.[34,35] The medium was removed, the cells were
washed with phosphate-buffered saline (PBS), and 1000 mL MTT
solution (1.5 mL MTT stock, 2 mg/mL in PBS, plus 28.5 mL
DMEM) was added to each well. RPE cells or HUVECs were
incubated at 37uC for 1 h. The formazan crystals that formed were
dissolved by the addition of 1000 mL DMSO per well. Absorption
was measured by a scanning multiwell spectrophotometer at
550 nm (Molecular Probes, Eugene, OR, USA). The results are
expressed as the mean percentage of proliferation in the control.
The control was set to 100% to allow easier interpretation of the
results.
Temsirolimus: Effect on HUVEC and RPE Cells
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Evaluation of Cellular Viability
To investigate the effects of different concentrations of
temsirolimus on viability of HUVECs and RPE cells, the cells
were brought to confluence on uncoated well plates, kept under
serum-free conditions for 24 h, and then treated with temsirolimus
at concentrations 0.005, 0.05, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5,
and 20 mg/mL for another 24 h. Then the MTT assay was
performed. The control cells were HUVECs or RPE cells of the
same passage.
Cell Proliferation
To determine the effect of temsirolimus on cellular proliferation,
HUVEC and RPE cells were seeded into a plain 6 well plate at a
density of 36104 cells/well with medium containing 10% fetal calf
serum. After four hours, final concentrations of 0.005, 0.05 and
0.5 mg/mL of temsirolimus and two controls were established in
the culture plate. Cells were then incubated under standard cell
culture conditions for 48 hrs. Then MTT solution (1.5 ml of
2 mg/ml in PBS plus 28.5 ml MEM) was added followed by 1
hour incubation at 37uC before 500 ml DMSO was added to
dissolve the formazan crystals. Absorption was measured by a
scanning multiwell spectrophotometer at 550 nm (Molecular
Probes, Eugene, OR, USA). The control cells were HUVECs or
RPE cells of the same passage. Controls were set to 100% to
simplify reading of results.
Migration Boyden Chamber Assay
Migration was observed by using microchemotaxis chambers
(Neuroprobe, Gaithersburg, Maryland, USA) as described by
Boyden with a few modifications.[36] The chamber consists of a
lower and an upper part divided by a polycarbonate membrane
(Nuclepore) with pores of 8 mm in diameter. In order to induce
chemotaxis, 200 ml medium containing 1 ng/ml VEGF-165
(VEGF-165, Sigma-Aldrich, St Louis, Missouri, USA) was filled
into the lower half of the chamber and covered with the
polycarbonate membrane previously coated with fibronectin
(coating time = 24 hrs at 8uC and at a concentration of 2 mg/
cm2). The upper half contained 16105 HUVEC or RPE cells cells
in 750 ml of the according cell culture medium containing 5%
FCS. Five chambers were prepared with three different concen-
trations of temsirolimus (0.005 mg/mL, 0.05 mg/mL, 0.5 mg/mL)
and two controls containing the same amount of solvent. Cells
were able to migrate for 24 hrs under standard cell culture
conditions. Then all non-migrated cells on top of the membrane
were removed by a cotton bud and the remaining cells on the
bottom side were fixed with methanol for 10 mins. After fixation, a
hematoxylin and eosin (HE) stain was used to make cells visible
under a magnification of 6200 using an inverted phasecontrast
microscope (Leica Microsystems GmbH, Solms, Germany). Cells
of five representative areas were photographed using a digital
camera (Leica, Solms, Germany) and manually counted using the
Leica LAS particle counting tool. The assay was repeated four
times on four different days. The results are presented as % control
and controls are set to 100% in order to simplify result
interpretation.
RNA Isolation and Real-Time Polymerase Chain Reaction
Total RNA was isolated from HUVEC and RPE cells by the
guanidinium thiocyanate-phenol-chloroform extraction method
(Stratagene, Heidelberg, Germany) and quantification of VEGF
(VEGF-A) and PDGF (PDGF-BB) mRNA was performed with
specific primers using a LightCycler System (Roche Diagnostics,
Mannheim, Germany) as described in our previous work [37].
Primers and probes were detected with ProbeFinder 2.04. Table 1
lists the primers used for RT-PCR. The level of VEGF and PDGF
mRNA was determined as the relative ratio (RR), which was
calculated by dividing the level of the respective mRNA by the
level of the 18S rRNA housekeeping gene in the same samples.
The ratios are expressed as decimals.
Protein Extraction and Western Blotting
HUVEC and RPE cells grown on 35-mm tissue culture dishes
were washed twice with ice-cold PBS, collected, and lysed in RIPA
cell lysis buffer. After centrifugation for 30 min at 19,000 6g in a
cold microfuge (5810R; Eppendorf, Hamburg, Germany), the
supernatant was transferred to fresh tubes and stored at –70uC for
future use. The protein content was measured by the bicinchoninic
acid protein assay (Pierce, Rockford, IL, USA). Denatured
proteins (1e2 mg) were separated by electrophoresis under
reducing conditions with the use of a 5% sodium dodecyl sulfate
(SDS)-polyacrylamide stacking gel and a 12% SDS-polyacryl-
amide separating gel, transferred with semidry blotting onto a
polyvinyl difluoride membrane (Roche), and probed with a mouse
anti-VEGF-antibody or a mouse anti-PDGF-antibody (both
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), as
described previously [34]. Chemiluminescence was detected with
an imager (LAS-1000; RayTest) and the generated light units.
Exposure times ranged between 1 and 10 min. Quantification was
performed on a computer (AIDA software; RayTest). Western blot
lanes were manually labeled (‘‘profile’’) and analyzed by the one
dimensional (1D) analysis mode of AIDA. Brightness was detected
by the program and divided through the height of the profile.
Resulting graphs were manually marked at the peak and the
volume below calculated as the integral by the software. An even
protein load in each lane was confirmed by staining of the
polyvinyl difluoride membranes with Coomassie Brilliant Blue
after the blotting procedure.
Detection of VEGF and PDGF Secretion by HUVEC and
RPE Cells
Cultures of HUVECs and RPE cells were grown to confluence
and treated as described above. Levels of VEGF and PDGF in the
culture supernatants were determined by enzyme-linked immu-
nosorbent assays (ELISAs). The supernatants were collected after
24 h, and the levels of VEGF-A and PDGF were quantified using a
VEGF (VEGF-A) or PDGF (PDGF-BB) QuantikineH ELISA
Assay Kit (R & D Systems, Wiesbaden, Germany) according to the
manufacturer’s instructions.
Statistical Analyses
All data were analyzed with SPSS 13.0 for Windows (SPSS,
Chicago, IL, USA). For all statistical tests, P , 0.05 was
considered significant.




VEGF - A 18 1540–1557 60 56 tgcccgctgctgtctaat
18 1592–1609 60 61 tctccgctctgagcaagg
PDGF - BB 18 1108–1125 60 56 tgatctccaacgcctgct
20 1156–1175 59 50 tcatgttcaggtccaactcg
doi:10.1371/journal.pone.0088203.t001
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Results of the MTT assay for evaluating proliferation are
presented as mean (SD) units of absorbance. Ten individual
samples per group were measured in triplicate. For the toxicity
study the results of the assay are presented as mean value displayed
as bars with standard deviation compared to the control. Results
from VEGF and PDGF ELISAs are presented as mean (SD) ratios
of each tested probe, which were normalized to the control.
Results of the RT-PCR are presented as mean (SD) ratios of the
investigated mRNA and 18S rRNA. All experiments were
performed at least in triplicate and repeated three times.
For statistical analyses a Wilcoxon test with a correction for
multiple testing was used.
Figure 1. Viability of HUVEC and pRPE cells. Viability of HUVECs and primary human RPE cells after treatment with various concentrations of
temsirolimus for 24 h, as measured by a colorimetric test (MTT). Untreated HUVECs or RPE cells of the same passage served as controls. Results are the
mean percentages of control cell survival from three experiments, each carried out in triplicate, with error bars indicating SEM. Temsirolimus
concentrations up to 12,5 mg/ml for RPE cells and 7,5 mg/mL for HUVEC showed no significant reduction in viability of either cell type (Wilcoxon test
with a correction for multiple testing) compared to controls. Data are expressed as means 6 SD. (*p,0.05 for HUVECs, #p,0.05 for RPE) Controls are
set to 100% to simplify result reading.
doi:10.1371/journal.pone.0088203.g001
Figure 2. Proliferation of HUVEC and pRPE cells. Inhibition of HUVEC (2A) and RPE cell (2B) proliferation after incubation with three different
concentrations of temsirolimus over 24 h measured by a colorimetric assay (MTT), (0 mg/mL = control). Data are expressed as means 6 SD and
results are displayed as % control, the control being set to 100%. (*p,0.05).
doi:10.1371/journal.pone.0088203.g002
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Results
Effects of Various Concentrations of Temsirolimus on
Viability, Proliferation and Migration of HUVECs and
Primary RPE Cells
HUVEC and RPE Cell Viability. To exclude that the
detected molecular interactions of temsirolimus in HUVEC and
RPE cells depend on toxic effects, viability of cells was investigated
after exposure to temsirolimus concentrations. Results of the MTT
assay showed no significant decrease in cellular viability in the cell
cultures after 24 h of exposure to temsirolimus at concentrations
between 0.005 and 7.5 mg/mL for HUVECs and 0.005 and
12.5 mg/mL for RPE cells (Fig. 1, Wilcoxon test with a correction
for multiple testing). In HUVEC, concentrations of 10 mg/mL and
higher showed an increasing reduction of cell viability. However,
.60% of the cells still showed activity. It must be noted though,
that an earlier study came to slightly different results: Zhang et al.
investigated the effect of temsirolimus and found signs of toxicity to
HUVECs at a concentration of 0.1 mg/mL.[38] They used this
concentration since another group showed that sirolimus signifi-
cantly inhibited proliferation in five different cell lines at this
concentration. No toxicity was however appreciated in this study
at the same concentration for these cells.[39,40] Moreover is the
intravenous concentration of temsirolimus (ToriselH, Pfizer, NY,
USA) in the treatment of renal cell carcinoma significantly higher
(30 mg). Therefore further studies are necessary to further
illuminate this issue.
Beginning with a concentration of 12.5 mg/mL, cellular viability
was reduced by .60% in a dose dependent manner. In RPE cells,
concentrations beginning from 15 mg/mL temsirolimus led to a
decrease of viability. However, even at the highest tested
concentration of 20 mg/mL still .60% of cells were active (Fig. 1).
Proliferation of HUVEC and RPE Cells. Cell proliferation
is one of the key factors involved in neovascularisation. Therefore,
we assessed HUVEC and RPE cell proliferation under different
concentrations of temsirolimus (0.005, 0.05, and 0.5 mg/mL). At
all tested temsirolimus concentrations (0.005, 0.05, and 0.5 mg/
mL) and in both tested cell lines, HUVEC and RPE cells, a
significant reduction in optical density was observed, compared to
the untreated control (Wilcoxon Test, p,0.05) (Fig. 2A and 2B).
Migration of HUVEC and RPE Cells. The effects of
temsirolimus on cellular migration were analyzed in vitro with a
chemotactic approach. The chemotactic migration using VEGF-
165, the isoform of VEGF that is most present in the eye, as an
attractant was evaluated by using the Boyden Chamber. In both
cell lines evaluated, HUVEC and RPE cells, there was a
significant, dose dependent reduction in cell migration observed
for temsirolimus concentrations (0.005, 0.05, and 0.5 mg/mL),
compared to the control (Fig. 3A, 3B and 3C). Of note, there was
also a significant difference in the decrease in-between the three
tested temsirolimus concentrations (0.005, 0.05, and 0.5 mg/mL)
with the strongest effect at the highest concentration of 0.5 mg/mL
temsirolimus.
Hypoxia Induced VEGF and PDGF Protein and mRNA
Expression in HUVECs and RPE Cells
Expression of VEGF and PDGF mRNA. Exposure to
hypoxia for 24 h led to a significant increase in VEGF and
PDGF mRNA expression in both HUVECs and RPE cells.
Treatment of both cell lines with 0.05 mg/mL temsirolimus
significantly reduced this hypoxia-induced increase in VEGF
(Fig. 4A and 4B) and PDGF mRNA (Fig. 5A and 5B) after 24 h.
Figure 3. Migration of HUVEC and pRPE cells. HUVEC and RPE cell migration was significantly inhibited after exposure to temsirolimus in a
dose-dependent manner (mg/mL) assessed by a modified Boyden chamber method. A) Example of cells attached to a permeable membrane at
different concentrations compared to an untreated control. B) Evaluation of migrated HUVEC in percent control after treatment with three different
temsirolimus concentrations. C) Migrated RPE cells compared to untreated cells in percent control. Data are expressed as means 6 SD with *p,0.05.
doi:10.1371/journal.pone.0088203.g003
Figure 4. VEGF mRNA expression in HUVEC and pRPE cells. VEGF (VEGF-A) expression of untreated HUVECs and primary RPE cells and after
exposure to hypoxia for 24 h, as measured by quantitative RT-PCR. When cells were exposed to hypoxia, a significant increase in VEGF mRNA could
be detected in both tested cell lines. When cells were additionally treated with 0.05 mg/ml temsirolimus, in HUVEC (A) and RPE cells (B) the hypoxia-
induced increase in VEGF mRNA expression was significantly less. Y-axis: RR of VEGF mRNA normalized to 18S rRNA, expressed in decimal format.
(*p,0.05).
doi:10.1371/journal.pone.0088203.g004
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Expression of VEGF and PDGF Protein
Western-Blotting from Cell Lysates. For verification that
the hypoxia-induced decrease of VEGF and PDGF in mRNA
transcription translates into increased protein synthesis, whole
cellular protein extracts of untreated control cells, cells exposed to
hypoxia without temsirolimus treatment, and cells treated with
0.05 mg/mL temsirolimus and exposure to hypoxia were analysed
by western blotting. Under hypoxic conditions, a marked increase
in both VEGF and PDGF expression could be detected compared
with the control. In HUVECs a 4.1x and 3.5x increase could be
appreciated for VEGF and PDGF respectively, while for RPE this
increase was even a little bit stronger with 4.4x for VEGF and 3.8x
for PDGF compared to the control. When HUVEC and RPE cells
were treated with 0.05 mg/mL temsirolimus and then exposed to
hypoxia however, expression of both VEGF and PDGF protein
was noticeably lower than after exposure to hypoxia only. In the
presence of temsirolimus the increase of VEGF and PDGF was
reduced to 1.2x and 0.9x in HUVECS and 1.9x and 2.0x in
respect of RPEs (Figure 6).
Detection of VEGF and PDGF Secretion in HUVECs and
RPE Cells. To investigate the effect of temsirolimus on VEGF
and PDGF (PDGF-BB) secretion after exposure to hypoxia, levels
of VEGF (Fig. 7A and 7B) and PDGF (Fig. 8A and 8B) in cell
culture supernatants were quantified using ELISA after 24 h. A
significant increase of the secretion of VEGF and PDGF by
cultured HUVECs and RPE cells was noted after 24 h of exposure
to hypoxia. Treatment of either cell line with temsirolimus
0.05 mg/mL reduced the secretion of VEGF and PDGF signifi-
cantly compared to controls.
Discussion
Without any doubt, intravitreal inhibition of VEGF revolution-
ized the therapy of a number of retinal vascular diseases [41,42].
The selective inhibition of VEGF and its isoforms is one of the
major strength of this treatment approach as it goes along with
only very few side effects [43], it is however conceivable that a
broader therapeutic approach involving the inhibition of key signal
pathways might be of interest especially for those patients, who do
not sufficiently benefit from the inhibition of a single molecule
such as VEGF [44].
The mammalian target of rapamycin (mTOR) is one of the key
signaling complexes that had been identified in conditions that are
linked with angiogenic features such as increased cellular
Figure 5. PDGF mRNA expression in HUVEC and pRPE cells. PDGF (PDGF-BB) expression of untreated HUVECs (A) and primary RPE cells (B)
and after exposure to hypoxia for 24 h, as measured by quantitative RT-PCR. Experiments were carried out in a similar manner as described in Figure
4. After hypoxia, additional treatment with 0.05 mg/mL temsirolimus led to a significantly less increase of PDGF expression. Y-axis: RR of PDGF mRNA
normalized to 18S rRNA, expressed in decimal format. (*p,0.05).
doi:10.1371/journal.pone.0088203.g005
Figure 6. Protein levels of VEGF and PDGF in HUVEC and pRPE
cells by Western Blot analysis. Representative Western blots
showing the expression of VEGF (VEGF-A) and PDGF (PDGF-BB) in
untreated HUVEC and RPE cells (Co) and treated with 0.05 mg/ml of
temsirolimus (Tem) after 24 h exposure to normoxic conditions or
hypoxia. Ten micrograms of protein were loaded per lane. An even
protein load in each lane was confirmed by staining of the polyvinyl
difluoride membranes with Coomassie Brilliant Blue after the blotting
procedure.
doi:10.1371/journal.pone.0088203.g006
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proliferation and migration [45] and evidence has been provided
that mTOR inhibition could be a suitable therapeutic strategy for
neovascular, degenerative retinal diseases [46].
We therefore investigated whether temsirolimus, a rapalog
(rapamycin analog), would have inhibitory features on RPE and
human umbilical vein endothelial cells (HUVEC) in non-toxic
concentrations in an in-vitro setting. As a first important result of
our experiments we could clearly show that temsirolimus
concentrations between 0.005 mg/mL and 7.5 mg/mL for HU-
VECs and 0.005 mg/mL and 12.5 mg/mL for RPE cells showed
no decreased viability (Figure 1). Always in mind that these results
are only in vitro, our data give a clear hint towards a broad
therapeutic range of the substance and that the concentrations
used for our further experiments (0.005 mg/mL – 0.5 mg/mL) can
be estimated as safe and non-toxic. MTOR consists of two protein
complexes: mTOR complex 1 and 2 (mTORC 1 & 2). Once a
growth factor such as VEGF binds to its receptor, particularly
VEGFR-2, a signaling cascade is started leading to activation of
PI3K and subsequent activation of protein kinase B (Akt) [29].
The effect of this is a regulation of mTORC 1 and a consecutive
up regulation of eukaryotic initiation factor 4E-binding protein
(4E-BP1) and the ribosomal protein S6 kinase (S6K) [47]. The
phosphorylation of these proteins eventually leads to increased
levels of several proteins that are important in cellular prolifera-
tion, migration and angiogenesis in RPE and vascular endothelial
cells [48–52], being crucial cellular features in the pathogenesis of
retinal vascular diseases such as neovascular AMD or proliferative
DR [53]. In our experiments, a significant dose dependent effect
on RPE cells as well as on HUVECs was seen in terms of
inhibiting proliferation (Figure 2) as well as migration (Figure 3)
after treatment with three different concentrations of temsirolimus,
suggesting that a significant reduction of these properties can be
Figure 7. Protein levels of VEGF in HUVEC and pRPE cell supernatants (ELISA). Inhibitory effect of temsirolimus on VEGF expression, as
measured by ELISA from supernatants. After exposure to 0.05 mg/ml temsirolimus for 24 h, a significant decrease in VEGF protein expression of both
HUVEC (A) and RPE cells (B) was detected. Each value was normalized to a standard curve of VEGF, and normalized to the untreated control of each
cell line. Data are expressed as means 6 SD. (*p,0.05).
doi:10.1371/journal.pone.0088203.g007
Figure 8. Protein levels of PDGF in HUVEC and pRPE cell supernatants (ELISA). Protein levels of PDGF were measured in a similar manner
as VEGF expression from supernatants with an ELISA assay. Cells were exposed to 0.05 mg/ml temsirolimus for 24 h. A significant decrease in PDGF
protein expression for both HUVEC (A) and RPE cells (B) was detected. Each value was normalized to a standard curve of PDGF, and normalized to the
untreated control of each cell line. Data are expressed as means 6 SD. (*p,0.05).
doi:10.1371/journal.pone.0088203.g008
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reached by directly targeting mTOR without specifically blocking
VEGF or other involved cytokines. However, in previous
investigations using cancer cell lines, the inhibition of mTOR
not only showed reduced activation in respect of cell proliferation
and migration but also decreased activity of PI3K/Akt itself,
suggesting susceptibility of even upstream mediators [54,55]. The
pathogenesis of ME in retinal vascular disease is multifactorial and
mainly results from a breakdown in the blood–retina barrier (BRB)
separating the neurosensory retina from the vascular components
of the eye. A disruption of the BRB involves an abnormal inflow of
fluid into the neurosensory tissue that often causes residual
accumulation of fluid in the intraretinal layers of the macula [56].
It is well known, that hypoxia is one of the leading causes for
increased expression of VEGF, including its isoforms leading to
the breakdown of the BRB [5,57]. VEGF is expressed by all
vascularized retinal tissues and there is clear evidence that in
response to hypoxia, augmented expression of VEGF in retinal
pericytes, RPE and endothelial cells occurs [58,59].
We therefore induced elevated VEGF and PDGF levels in both
RPE and endothelial cells by exposing them to hypoxic conditions
and analyzed a possible effect of temsirolimus in respect of VEGF
and PDGF levels on RNA and protein levels. Our results implicate
that a significant reduction of VEGF and PDGF levels can be
achieved by intervening at the level of mTOR, a downstream
mediator of VEGFR-2 and VEGF, by temsirolimus following
increased growth factor expression by induction of hypoxia in both
cell types (Figure 4, 5 and Table S1). We furthermore proved that
this reduction eventually lead to a decrease in protein levels for
both cytokines qualitatively (Figure 6) as well as quantitatively
(Figure 7).
Mizukami et al. previously postulated however, that not only
hypoxia, by stabilization of HIF-1, cellular receptors such as
EGFR and IGF-IR and other growth factors (e.g. PDGF) induce
the production of VEGF and its receptors but also PI3K and its
downstream signaling pathway compounds including mTOR itself
might trigger their production [60–64]. The strong decrease of
VEGF expression in our experiments might therefore also
emphasize the idea of mTOR being directly involved in the
expression of VEGF and other growth factors.
Our experiments clearly show that temsirolimus has a broad
therapeutic range and even low concentrations were capable of
inhibiting proliferation and migration significantly in RPE and
endothelial cells. Our results additionally suggest that temsirolimus
is able to directly decrease the expression of growth factors such as
VEGF and PDGF both on RNA and protein levels.
These findings are particularly interesting as the combination of
an anti-VEGF drug and temsirolimus might have complimentary
therapeutic effects for patients who do not benefit from repeated
intravitreal anti-VEGF injections. This combination however, has
not been studied extensively and therefore no valid statement
regarding synergistic effects with anti-VEGF drugs can be made.
Due to the very low concentrations that are needed to achieve
significant effects and currently ongoing studies to evaluate the
intravitreal biocompatibility of sirolimus [65], another mTOR
inhibitor of the same family, we believe that toxic side effects
described, when taken orally in order to treat different cancers
would be less likely [66].
Temsirolimus is a well-tolerated and approved drug for renal
cell carcinoma [67]. Our results show first evidence that inhibiting
mTOR, a central signaling pathway in the complex cascade
underlying neovascularization and angiogenesis, with temsirolimus
lead to a decrease in the production of the key cytokine VEGF as
well as other growth factors such as PDGF and also reduce cellular
events typically associated with angiogenesis.
Our very early results on the effect of mTOR inhibition in this
context are promising, although they are solely in-vitro with typical
limitations including investigating mono cell cultures and cells that
are not in the proper physiological state. (Figure S1)
We nonetheless believe, that temsirolimus might have a role in
the treatment of ocular neovascular diseases in the future and
further investigations should be pursued to gain additional
information regarding clinical outcome as well as biocompatibility.
Supporting Information
Figure S1 Typical limitations of mono cell culture based
experiments include cells that are not in the proper physiological
state. Photographs of both human umbilical vein endothelial cells
(HUVEC) [A] and primary retinal pigment epithelial cells (RPE)
[B] that were used for our experiments are shown at near
confluence.
(JPG)
Table S1 Results for normalized ratios of rtPCR using
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